Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Tufts Medical Center
Study ID
NCT06365060
Status
Recruiting
Apply to this trial

Conditions

  • Smoldering Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Study Details

In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.

Key Dates

Start date
May 1, 2024
Status verified
Aug 2025
Primary completion
Feb 27, 2029
Completion
Feb 27, 2029

Study Design

Enrollment
400 participants (estimated)

Primary Outcome Measure

Creating a network to enroll patients on a collaborative study requiring marrow and blood specimens, to collect data for a training set of likelihood statistics and to plan a future validation study. [ Time Frame: 5 years ]

Central Contacts

Locations (13)

FacilityCityStateZIPSite coordinators
University of Alabama HospitalBirminghamAlabama35233
Megan Maier
[email protected]
205-882-1041
Susan Bal, MD (PRINCIPAL_INVESTIGATOR)
Cedars-Sinai Medical CenterLos AngelesCalifornia90048
Robert Vescio, MD (PRINCIPAL_INVESTIGATOR)
University of California, San FranciscoSan FranciscoCalifornia94143
Jane Greenaway
[email protected]
415-269-8259
Tom Martin, MD (PRINCIPAL_INVESTIGATOR)
Cleveland Clinic Florida, Weston HospitalWestonFlorida33331
Chakra Chaulagain, MD (PRINCIPAL_INVESTIGATOR)
Tufts Medical CenterBostonMassachusetts02111
Denis Toskic
[email protected]
617-636-5907
Raymond Comenzo, MD (PRINCIPAL_INVESTIGATOR)
Columbia University Irving Medical CenterNew YorkNew York10032
CUIMC Navigators
[email protected]
Suzanne Lentzsch, MD (PRINCIPAL_INVESTIGATOR)
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Bayley Axelrod
[email protected]
Heather Landau, MD (PRINCIPAL_INVESTIGATOR)
Atrium Health Levine Cancer InstituteCharlotteNorth Carolina28204
Courtney Schepel
[email protected]
980-292-0817
Cindy Varga, MD (PRINCIPAL_INVESTIGATOR)
UNC Lineberger Comprehensive Cancer CenterDurhamNorth Carolina27705
Kendall Conder
[email protected]
919-962-7473
Sascha Tuchman, MD (PRINCIPAL_INVESTIGATOR)
The Ohio State University Comprehensive Cancer CenterColumbusOhio43210
Naresh Bumma, MD (PRINCIPAL_INVESTIGATOR)
UT Southwestern, Harold C. Simmons Comprehensive Cancer CenterDallasTexas75390
Larry Anderson, MD (PRINCIPAL_INVESTIGATOR)
University of Utah, Huntsman Cancer HospitalSalt Lake CityUtah84112
Sharmilee Nuli
[email protected]
801-213-6203
Amandeep Godara, MD (PRINCIPAL_INVESTIGATOR)
VCU Medical CenterRichmondVirginia23219
Tyler Phillips
[email protected]
804-828-9085
Hashim Mann, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

By research site
University of Alabama Hospital· Birmingham, ALCedars-Sinai Medical Center· Los Angeles, CAUniversity of California, San Francisco· San Francisco, CACleveland Clinic Florida, Weston Hospital· Weston, FLTufts Medical Center· Boston, MAColumbia University Irving Medical Center· New York, NY

Related Studies